SILENCE THERAP. SP.ADR/1 - Asset Resilience Ratio
SILENCE THERAP. SP.ADR/1 (XRP2) has an Asset Resilience Ratio of 56.17% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is SILENCE THERAP. SP.ADR/1's working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how SILENCE THERAP. SP.ADR/1's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is SILENCE THERAP. SP.ADR/1's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down SILENCE THERAP. SP.ADR/1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore SILENCE THERAP. SP.ADR/1 long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €73.84 Million | 56.17% |
| Total Liquid Assets | €73.84 Million | 56.17% |
Asset Resilience Insights
- Very High Liquidity: SILENCE THERAP. SP.ADR/1 maintains exceptional liquid asset reserves at 56.17% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
SILENCE THERAP. SP.ADR/1 Industry Peers by Asset Resilience Ratio
Compare SILENCE THERAP. SP.ADR/1's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for SILENCE THERAP. SP.ADR/1 (2021–2025)
The table below shows the annual Asset Resilience Ratio data for SILENCE THERAP. SP.ADR/1.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 56.17% | €73.84 Million ≈ $86.32 Million |
€131.44 Million ≈ $153.67 Million |
+43.34pp |
| 2024-12-31 | 12.83% | €26.00 Million ≈ $30.40 Million |
€202.63 Million ≈ $236.90 Million |
-- |
| 2023-12-31 | 0.00% | €0.00 ≈ $0.00 |
€119.45 Million ≈ $139.65 Million |
-- |
| 2022-12-31 | 15.19% | €19.76 Million ≈ $23.10 Million |
€130.10 Million ≈ $152.10 Million |
-- |
| 2021-12-31 | 0.00% | €0.00 ≈ $0.00 |
€129.83 Million ≈ $151.78 Million |
-- |
About SILENCE THERAP. SP.ADR/1
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated … Read more